Combination of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma – The ASCO Post

By The ASCO Post StaffDecember 10, 2019 Combination therapy with the programmed cell death ligand 1 inhibitor atezolizumab and the vascular endothelial growth factor inhibitor bevacizumab significantly improved overall and progression-free survival in patients with unresectable hepatocellular carcinoma…

Read the full article here

Related Articles